Senokot 7.5mg/5ml Syrup
*Company:
Reckitt Benckiser Ireland LimitedStatus:
No Recent UpdateLegal Category:
Supply through pharmacy onlyActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 06 August 2021
File name
SPC Senokot Syrup.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through pharmacy only
Updated on 06 August 2021
File name
PIL Senokot Syrup.pdf
Reasons for updating
- Change to section 2 - excipient warnings
Updated on 15 January 2020
File name
Senokot 7.5mg-5ml Syrup.pdf
Reasons for updating
- New PIL for new product
Updated on 08 January 2019
File name
Senokot 7.5mg_5ml Syrup SmPC.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Additional information added to SmPC due to CCDS update
Updated on 05 February 2013
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 05 February 2013
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In Section 6.3, the shelf-life has been reduced to 13 months.
In section 10, the date of revision of the text has been changed to November 2012.
In section 10, the date of revision of the text has been changed to November 2012.
Updated on 05 February 2013
Reasons for updating
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In Section 6.3, the shelf-life has been reduced to 13 months.
In section 10, the date of revision of the text has been changed to November 2012.
In section 10, the date of revision of the text has been changed to November 2012.
Updated on 24 November 2009
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Inclusion of the following warning in Section 4.4 of the SPC
The Physician should be satisfied that there are no underlying gastro intestinal pathology masking as constipation before recommending this product. Enquiry should be made about bowel habit, (particularly recent changes in bowel habit such as persistent diarrhoea or constipation), evacuation and bleeding per rectum
The Physician should be satisfied that there are no underlying gastro intestinal pathology masking as constipation before recommending this product. Enquiry should be made about bowel habit, (particularly recent changes in bowel habit such as persistent diarrhoea or constipation), evacuation and bleeding per rectum
Updated on 24 November 2009
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
Free text change information supplied by the pharmaceutical company
Inclusion of the following warning in Section 4.4 of the SPC
The Physician should be satisfied that there are no underlying gastro intestinal pathology masking as constipation before recommending this product. Enquiry should be made about bowel habit, (particularly recent changes in bowel habit such as persistent diarrhoea or constipation), evacuation and bleeding per rectum
The Physician should be satisfied that there are no underlying gastro intestinal pathology masking as constipation before recommending this product. Enquiry should be made about bowel habit, (particularly recent changes in bowel habit such as persistent diarrhoea or constipation), evacuation and bleeding per rectum
Updated on 16 May 2007
Reasons for updating
- Change to marketing authorisation holder address
- SPC retired pending re-submission
Legal category:Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
SECTION 7. Change of marketing authorisation holder address to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
Updated on 16 May 2007
Reasons for updating
- Change to marketing authorisation holder address
- SPC retired pending re-submission
Free text change information supplied by the pharmaceutical company
SECTION 7. Change of marketing authorisation holder address to: 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.
Updated on 04 August 2006
Reasons for updating
- New SPC for new product
Legal category:Supply through pharmacy only
Updated on 04 August 2006
Reasons for updating
- New SPC for new product